Best Agrolife Limited has released its Q3 FY26 financial results along with the earnings conference call transcript, revealing mixed performance with revenue decline but improved operational efficiency. The company disclosed these results through regulatory filings and held its earnings call on February 9, 2026.

Financial Performance Overview

The company's Q3 FY26 results reflect challenging market conditions with revenue from operations declining significantly due to weather-related disruptions. Despite revenue pressures, the company demonstrated improved cost management and operational discipline.

Weather Impact and Market Challenges

Managing Director Vimal Kumar explained that Q3 FY26 was significantly impacted by unusual weather conditions. October 2025 witnessed exceptionally high rainfall across the country, with India recording rainfall nearly 49% higher than the long-period average, making it the second highest October rainfall since 2001. These conditions disrupted sowing patterns and the overall cropping cycle.

The excess rainfall particularly affected key markets in West and Central India, impacting soybean spray programs in Madhya Pradesh and South Rajasthan. Additionally, pest pressure in paddy crops remained very low, reducing demand for crop-protection products during the quarter.

Nine-Month Performance Analysis

For the nine-month period (9M FY26), the company reported continued revenue pressure but maintained reasonable profitability metrics.

CFO Vikas Jain noted that the nine-month year-on-year sales decline of 28% comprised 23% volume decline and 5% price variation. Importantly, the patented portfolio remained relatively stable with only a 5% reduction, while the non-patent portfolio declined by 48%.

Patent Product Portfolio Progress

The company highlighted strong performance from its patent product portfolio, particularly two newly launched combinations - BestMan and Fetagen. Both products received strong acceptance from the farming community, with each crossing more than 4 lakh treated acres in their first year despite late registration.

Executive Director Surendra Sai reported significant progress on the intellectual property front, with three patents secured for novel combination formulations and one process patent for an intermediate with export potential. The company also filed four international patent applications and received its first grant in nano-formulation technology.

International Business Development

The company is making steady progress in export markets with registrations for patented products in Sri Lanka advancing well. Dossier preparation is underway for products in Vietnam and Morocco, while the company continues discussions around pesticides and patented nano-urea. The company completed its third export shipment to Sudan on a cash basis.

Management Outlook

Management expressed confidence in long-term business fundamentals despite near-term challenges. The company is implementing various productivity improvement measures including database inventory control, ERP analytics for sales tracking, comprehensive sales team applications, and digital dealer-farmer connectivity platforms.

For FY26, management expects to close the year between ₹1,300-1,400 crores in revenue with EBITDA margins around 12%. The company anticipates growth recovery from FY27 onwards, targeting revenue levels of ₹1,600-1,800 crores within the next two years.

Source: Best Agrolife Limited Q3 FY26 earnings conference call transcript

Best Agrolife Limited has submitted its monitoring agency report for the quarter ended December 31, 2025, to stock exchanges, detailing the utilization of proceeds from its preferential issue of convertible warrants. The report, prepared by CRISIL Limited as the monitoring agency, reveals no utilization of issue proceeds during the reported quarter.

Issue Details and Revisions

The company's preferential issue was conducted from December 17, 2024, to December 26, 2024, involving convertible warrants. The issue size was revised from Rs 200.00 crore to Rs 150.00 crore due to undersubscription of warrants.

Utilization Status and Fund Allocation

The monitoring report indicates that no funds were utilized during the quarter ended December 31, 2025. The company has received Rs 37.50 crore as subscription amount, representing 25% of the issue size, with the balance Rs 112.50 crore yet to be received from warrant holders.

Warrant Conversion Challenges

The report highlights significant market developments affecting warrant conversion prospects. Following a stock split from Rs 10.00 to Rs 1.00 per share and a bonus issue in the ratio of 1:2, the warrant exercise price was proportionately revised to Rs 64.00 per share. However, as of January 27, 2026, the company's equity shares were trading at approximately Rs 22.00 per share, substantially below the exercise price.

Conversion Timeline and Risk Factors

Warrant holders have 18 months from the allotment date of December 27, 2024, to exercise their conversion rights. The monitoring agency has noted an inherent risk of non-exercise of conversion rights if market prices continue to remain below the exercise price of Rs 64.00 per share, which may impact the realization of proceeds from the warrants.

Regulatory Compliance

The report confirms compliance with Regulation 32(6) of SEBI Listing Obligations and Disclosure Requirements Regulations, 2015, and Regulation 162A of SEBI Issue of Capital and Disclosure Requirements Regulations, 2018. CRISIL Limited, serving as the monitoring agency under the agreement dated October 20, 2024, has reported no deviations from disclosed objects during the quarter.